Date:11/25/2009

n H5N1, the Replikin Counts in the same two genes exhibit the reverse characteristics, that is, low infectivity and high lethality (Figure); and in this case again, the Counts correspond to what follows clinically, that is, low infectivity and high lethality cases. The distinctly separate and opposite states in these genes is therefore observed both intra-strain in H1N1, and inter-strain in H1N1 vs. H5N1. This represents an important validation by the method of "double differentiation" of the independent function of these two genes (refs). Dr. Samuel Bogoch is co-founder with Dr. Elenore Bogoch of Replikins Ltd., a Boston biotechnology firm which attracted worldwide attention for successfully predicting the current H1N1 outbreak a full year ahead of time. Dr. Bogoch is again making waves by stating that as of this month, this cycle of the outbreak has peaked. FluForecast(R) is showing declining levels of key Replikins sequences in the virus. High levels of these sequences have been consistently linked with the lethality of viruses in major epidemics, and their reduction is indicative that the current outbreak is declining from a peak level earlier this year. The Company has announced the formation of WorldVaccines(TM) Ltd to test and distribute FluForecast(R) and Replikins' synthetic vaccines against emerging diseases to address the "niche" of 6 billion people who are not receiving timely biological vaccines.

Logo: http://www.ereleases.com/pr/2009-Replikins-Logo.jpg

References:

1) US Patent Office publications on Replikins 2002-2009; 2) BogochS, Bogoch,ES. Replikins: the Biochemistry of Rapid Replication, Begell House, New York, 2005; 3) Website <replikins.com> Replikins Press 2006-2009; 4) CDC Weekly Reports website (google "FluView"); 5) Betsy McKay, Wall Street Journal, page A3, November 21-22, 2009; 6) Jackwood, M. et al. Efficacy of a Replik
'/>"/>

Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
2. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
3. New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution
4. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
5. Scientists use math modeling to predict unknown biological mechanism of regulation
6. Quantel Signs a Distribution Agreement With US-based National Biological
7. Senate President Therese Murray, Massachusetts Life Sciences Center, and Howard Hughes Medical Institute Join Marine Biological Laboratory (MBL) for Loeb Laboratory Groundbreaking Ceremony
8. Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
9. Nucleix Researchers Discover DNA Evidence May Easily be Falsified: Company Develops New Detection Technology for Preventing Biological Identity Theft
10. Nanoelectronic transistor combined with biological machine could lead to better electronics
11. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center